70 related articles for article (PubMed ID: 27521706)
1. Dual-targeting hybrid peptide-conjugated doxorubicin for drug resistance reversal in breast cancer.
Sheng Y; You Y; Chen Y
Int J Pharm; 2016 Oct; 512(1):1-13. PubMed ID: 27521706
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of A-B-C-type amphiphilic copolymer on reversal of drug resistance in MCF-7/ADR breast carcinoma.
Zhang L; Lu J; Qiu L
Int J Nanomedicine; 2016; 11():5205-5220. PubMed ID: 27785023
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological activities of a 3'-azido analogue of Doxorubicin against drug-resistant cancer cells.
Yu S; Zhang G; Zhang W; Luo H; Qiu L; Liu Q; Sun D; Wang PG; Wang F
Int J Mol Sci; 2012; 13(3):3671-3684. PubMed ID: 22489175
[TBL] [Abstract][Full Text] [Related]
4. Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy.
Yu H; Li JM; Deng K; Zhou W; Wang CX; Wang Q; Li KH; Zhao HY; Huang SW
Theranostics; 2019; 9(23):7033-7050. PubMed ID: 31660085
[TBL] [Abstract][Full Text] [Related]
5. Magnetic And pH Dual-Responsive Nanoparticles For Synergistic Drug-Resistant Breast Cancer Chemo/Photodynamic Therapy.
Wang D; Li X; Li X; Kang A; Sun L; Sun M; Yang F; Xu C
Int J Nanomedicine; 2019; 14():7665-7679. PubMed ID: 31571870
[TBL] [Abstract][Full Text] [Related]
6. Aptamer-Peptide Conjugates as Targeted Chemosensitizers for Breast Cancer Treatment.
Tan Y; Li Y; Qu YX; Su Y; Peng Y; Zhao Z; Fu T; Wang XQ; Tan W
ACS Appl Mater Interfaces; 2021 Mar; 13(8):9436-9444. PubMed ID: 33306339
[TBL] [Abstract][Full Text] [Related]
7. New Transferrin Receptor-Targeted Peptide-Doxorubicin Conjugates: Synthesis and In Vitro Antitumor Activity.
Yu J; Mao X; Yang X; Zhao G; Li S
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675578
[TBL] [Abstract][Full Text] [Related]
8. Combination of tanshinone IIA and doxorubicin possesses synergism and attenuation effects on doxorubicin in the treatment of breast cancer.
Li K; Liu W; Zhao Q; Wu C; Fan C; Lai H; Li S
Phytother Res; 2019 Jun; 33(6):1658-1669. PubMed ID: 30945389
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model.
Christowitz C; Davis T; Isaacs A; van Niekerk G; Hattingh S; Engelbrecht AM
BMC Cancer; 2019 Aug; 19(1):757. PubMed ID: 31370818
[TBL] [Abstract][Full Text] [Related]
10. Peptide-Drug Conjugate Targeting Keratin 1 Inhibits Triple-Negative Breast Cancer in Mice.
Ziaei E; Paiva IM; Yao SJ; Sarrami N; Mehinrad P; Lai J; Lavasanifar A; Kaur K
Mol Pharm; 2023 Jul; 20(7):3570-3577. PubMed ID: 37307328
[TBL] [Abstract][Full Text] [Related]
11. Conjugate of Doxorubicin to Albumin-Binding Peptide Outperforms Aldoxorubicin.
Yousefpour P; Ahn L; Tewksbury J; Saha S; Costa SA; Bellucci JJ; Li X; Chilkoti A
Small; 2019 Mar; 15(12):e1804452. PubMed ID: 30756483
[TBL] [Abstract][Full Text] [Related]
12. A comparative
Karim S; Alghanmi AN; Jamal M; Alkreathy H; Jamal A; Alkhatabi HA; Bazuhair M; Ahmad A
Oncol Res; 2024; 32(5):817-830. PubMed ID: 38686050
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression
Yang X; Shang P; Yu B; Jin Q; Liao J; Wang L; Ji J; Guo X
Acta Pharm Sin B; 2021 Sep; 11(9):2819-2834. PubMed ID: 34589399
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer.
Saghaeidehkordi A; Chen S; Yang S; Kaur K
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34063098
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-transferrin conjugate alters mitochondrial homeostasis and energy metabolism in human breast cancer cells.
Wigner P; Zielinski K; Labieniec-Watala M; Marczak A; Szwed M
Sci Rep; 2021 Feb; 11(1):4544. PubMed ID: 33633284
[TBL] [Abstract][Full Text] [Related]
16. APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells.
Stefanski CD; Keffler K; McClintock S; Milac L; Prosperi JR
Neoplasia; 2019 Dec; 21(12):1143-1150. PubMed ID: 31759252
[TBL] [Abstract][Full Text] [Related]
17. An energy-blocking nanoparticle decorated with anti-VEGF antibody to reverse chemotherapeutic drug resistance.
Gu LQ; Cui PF; Xing L; He YJ; Chang X; Zhou TJ; Liu Y; Li L; Jiang HL
RSC Adv; 2019 Apr; 9(21):12110-12123. PubMed ID: 35548379
[TBL] [Abstract][Full Text] [Related]
18. Novel Doxorubicin Derivatives: Synthesis and Cytotoxicity Study in 2D and 3D
Akasov R; Drozdova M; Zaytseva-Zotova D; Leko M; Chelushkin P; Marc A; Chevalot I; Burov S; Klyachko N; Vandamme T; Markvicheva E
Adv Pharm Bull; 2017 Dec; 7(4):593-601. PubMed ID: 29399549
[No Abstract] [Full Text] [Related]
19. Reversing Chemotherapy Resistance by a Synergy between Lysosomal pH-Activated Mitochondrial Drug Delivery and Erlotinib-Mediated Drug Efflux Inhibition.
Cheng F; Pan Q; Gao W; Pu Y; Luo K; He B
ACS Appl Mater Interfaces; 2021 Jun; ():. PubMed ID: 34130450
[TBL] [Abstract][Full Text] [Related]
20. Label-free recognition of drug resistance via impedimetric screening of breast cancer cells.
Eker B; Meissner R; Bertsch A; Mehta K; Renaud P
PLoS One; 2013; 8(3):e57423. PubMed ID: 23483910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
